XML 63 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
License agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Feb. 28, 2018
USD ($)
Jan. 08, 2018
$ / shares
Dec. 31, 2017
USD ($)
[1]
Related Party Transaction [Line Items]                
Long term investment   $ 121,381   $ 121,381       $ 134,356
Research and development expense   292,527 $ 269,557 893,719 $ 879,263      
Unrealized gain (loss) on long term investments   (9,949) $ 23,045 (21,911) $ (2,343)      
Syros Pharmaceuticals, Inc.                
Related Party Transaction [Line Items]                
Number of program targets | item 7              
Upfront payment under license agreement $ 10,000              
Long term investment   $ 11,200   $ 11,200        
Ownership percentage (as a percent)   3.00%   3.00%        
Unrealized gain (loss) on long term investments   $ 1,600   $ 2,200        
Syros Pharmaceuticals, Inc. | Stock purchase agreement                
Related Party Transaction [Line Items]                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.8              
Purchase price of common stock $ 10,000              
Per share price | $ / shares $ 12.61           $ 9.77  
Lock-up period 12 months              
Discount for lack of marketability $ 100              
Fair value of shares on the issuance date 7,600              
Long term investment 7,600              
Research and development expense $ 2,400              
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement                
Related Party Transaction [Line Items]                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.1              
Purchase price of common stock $ 1,400              
Per share price | $ / shares $ 9.55              
Long term investment           $ 1,400    
Syros Pharmaceuticals, Inc. | Maximum                
Related Party Transaction [Line Items]                
Target selection and option exercise fee payment $ 54,000              
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum                
Related Party Transaction [Line Items]                
Additional milestone payments under the license agreement 50,000              
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum                
Related Party Transaction [Line Items]                
Additional milestone payments under the license agreement $ 65,000              
[1] The condensed consolidated balance sheet at December 31, 2017 has been derived from the audited financial statements at that date.